Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Sponsor: MorphoSys AG

Expanded Access
Approved for Marketing
Sponsor score: 0

ClinicalTrials ID:NCT04300803

The Expanded Access Program for Tafasitamab offers treatment to U.S. patients with relapsed/refractory DLBCL who have tried at least one anti-CD20 regimen. Eligible patients include those with primary refractory disease and double/triple hit status, lacking other treatment options. Tafasitamab is administered at 12 mg/kg in 4-week cycles, transitioning from weekly to bi-weekly dosing.

Patient Parameters

Program Overview

Expanded Access Program (EAP) to provide Tafasitamab (MOR208) to eligible patients with relapsed or refractory Diffuse Large B Cell Lymphoma. Access to MorphoSys´ EAP can be requested by contacting the respective CRO Clinigen (tafasitamab@clinigengroup.com).

Description

This program is intended to provide access to patients with relapsed and/or refractory DLBCL who had at least one prior anti-CD20 containing regimen. Patients with primary refractory disease and double/triple hit status are also eligible. Patients considering this access program should have no other therapeutic option, and are not eligible for other clinical trials. The expanded access program (MOR208N001) is currently available in the United States only.

Eligibility Criteria

Exclusion Criteria

  1. Patients who have other histological type of lymphoma, e.g. indolent Non-Hodgkin lymphoma (NHL), Primary mediastinal B-cell lymphoma (PMBL) or Burkitt Lymphoma

  2. Patients who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period with lenalidomide

  3. Patients with:

    1. Known active bacterial and viral and fungal infections
    2. Serology of chronic active viral Hepatitis B and/or C-Hepatitis
    3. Known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV)

  4. Patients who are unable to participate in the lenalidomide REMS program

Get This Program In Your Inbox

You can sign up and apply your patients for this program.